Familial Adenomatous Polyposis Treatment Market Report 2026

The familial adenomatous polyposis treatment market size has grown rapidly in recent years. It will grow from $1.5 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to early identification of inherited colorectal disorders, growth in genetic testing availability, expansion of colorectal cancer prevention programs, increased awareness of hereditary cancers, improved endoscopic technologies.

The familial adenomatous polyposis treatment market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to advancements in gene-based therapies, increased adoption of personalized treatment plans, expansion of preventive oncology programs, growing use of AI-assisted diagnostics, rising investment in rare disease research. Major trends in the forecast period include increased focus on genetic screening and counseling, growing use of preventive surgical interventions, rising adoption of targeted drug therapies, expansion of long-term surveillance programs, integration of AI in early cancer risk detection.

Rising healthcare expenditure is expected to drive growth in the familial adenomatous polyposis (FAP) treatment market in the coming years. Healthcare spending encompasses total expenditures on medical services, treatments, pharmaceuticals, and health-related infrastructure by individuals, governments, and private organizations to maintain and improve health outcomes. The increase in healthcare spending is driven by an aging population and advances in medical technology. As life expectancy rises, a larger number of elderly individuals require long-term care, chronic disease management, and frequent medical interventions, resulting in higher healthcare costs. This growing expenditure supports research and development for FAP treatments, leading to innovations in genetic testing, targeted therapies, and minimally invasive procedures that enhance early detection, disease management, and patient outcomes. For example, in December 2024, the Centers for Medicare & Medicaid Services, a US federal agency, reported that Medicare spending in the US rose by 8.1%, reaching $1.02 trillion, representing 21% of total national health expenditures (NHE). Therefore, the expansion of healthcare spending is fueling the growth of the FAP treatment market.

The rise in minimally invasive procedures is also expected to propel growth in the familial adenomatous polyposis (FAP) treatment market. Minimally invasive procedures use small incisions, specialized instruments, or imaging guidance to diagnose or treat conditions with less trauma, shorter recovery times, and lower risk compared to traditional surgery. This increase is driven by advances in medical technology and patient demand for quicker recovery. Innovations in surgical techniques, robotics, and imaging have enabled smaller incisions, reducing complications and hospital stays. Minimally invasive procedures improve polyp removal and surveillance in FAP treatment by enabling early detection, precise excision, and fewer complications, delaying disease progression and minimizing the need for extensive surgery. For instance, in 2023, the American Society of Plastic Surgeons, a US-based organization, reported a 7% year-over-year growth in minimally invasive procedures in the US. Therefore, the growing adoption of minimally invasive procedures is driving the FAP treatment market.

Leading companies in the familial adenomatous polyposis (FAP) treatment market are advancing therapeutic approaches to improve patient outcomes and provide innovative solutions. These advancements include new drug formulations and targeted therapies aimed at reducing polyp formation and slowing disease progression. For example, in June 2024, Biodexa Pharmaceuticals PLC, a UK-based biopharmaceutical company, reported positive results from its Phase 2 clinical trial of eRapa for FAP treatment. The trial demonstrated a 75% non-progression rate and a 17% median reduction in polyp burden over 12 months. In Cohort 2, participants achieved an 81% non-progression rate and a 29% reduction in polyps with a specific dosing regimen. The treatment was well-tolerated, with a 95% compliance rate. These promising findings pave the way for a Phase 3 trial involving approximately 168 high-risk FAP patients, potentially shifting the treatment paradigm from surgical intervention to effective medical therapy.

Major companies operating in the familial adenomatous polyposis treatment market are Mayo Clinic, Mount Sinai Health System, Johns Hopkins Medicine, Cleveland Clinic, UCLA Health, Houston Methodist Hospital, Scripps Health, Duke University Health System, Texas Children's Hospital, Massachusetts General Hospital, Inova Health Care Services, Brigham and Women's Hospital, Stanford Health Care, Barnes-Jewish Hospital, Northwestern Medicine, Geisinger Health, Max Healthcare, Sapience Therapeutics Inc., Frederick Gastroenterology Associates PA, Therapyx.

North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial adenomatous polyposis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the familial adenomatous polyposis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the familial adenomatous polyposis treatment market by raising prices for imported genetic testing kits, pharmaceuticals, endoscopic equipment, and surgical tools. Hospitals and diagnostic centers in Asia-Pacific and Europe are most affected due to reliance on global medical technology suppliers. These higher costs can delay early diagnosis and preventive treatment. However, tariffs are encouraging domestic production of diagnostics and therapeutics, improving long-term care accessibility.

The familial adenomatous polyposis treatment market research report is one of a series of new reports that provides familial adenomatous polyposis treatment market statistics, including familial adenomatous polyposis treatment industry global market size, regional shares, competitors with a familial adenomatous polyposis treatment market share, detailed familial adenomatous polyposis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the familial adenomatous polyposis treatment industry. This familial adenomatous polyposis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Familial adenomatous polyposis (FAP) treatment involves medical and surgical strategies to manage FAP, a genetic disorder marked by the formation of numerous precancerous polyps in the colon and rectum. The primary aim of treatment is to prevent colorectal cancer, which nearly always occurs if the condition is left untreated.

The main products for familial adenomatous polyposis treatment include icosapent, eflornithine hydrochloride, aspirin, cetuximab oral formulation (CEQ)-508, and others. Icosapent is a purified eicosapentaenoic acid (EPA) derivative primarily used to lower triglyceride levels. It is indicated for attenuated FAP, familial adenomatous polyposis, Gardner syndrome, and Turcot syndrome, and is used to manage symptoms such as bloody stool, unexplained diarrhea, abdominal cramps, bloating, weight loss, lethargy, and vomiting. Treatments are applied for colorectal cancer prevention, genetic counseling, and surgical intervention by various end-users, including clinics, hospitals, diagnostic centers, home healthcare services, and others.

The familial adenomatous polyposis treatment market consists of sales of non-steroidal anti-inflammatory drugs, chemo preventive agents and targeted therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.